Status:
COMPLETED
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
Eligibility Criteria
Inclusion
- Males and females 18-60 years
- Mild asthma
- Atopic to allergens
Exclusion
- Unstable asthma
- Smokers or recent ex-smokers
- Recent allergen challenge
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00877539
Start Date
June 1 2009
End Date
July 1 2010
Last Update
September 28 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
London, United Kingdom, SE1 1YR
2
Pfizer Investigational Site
Manchester, United Kingdom, M23 9QZ